Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bracco Diagnostics, the US-based subsidiary of Bracco Imaging and part of the Bracco Group, and Lantheus Medical Imaging, have signed an agreement for Lantheus to co-promote Bracco's CardioGen-82, a myocardial perfusion positron emission tomography imaging agent.
Subscribe to our email newsletter
CardioGen-82 is said to be the only generator-based positron emission tomography (PET) perfusion agent approved by the FDA and reimbursed for the evaluation of coronary artery disease.
CardioGen-82 PET myocardial perfusion imaging has experienced double digit year-over-year growth since 2003. It is expected that this agreement will further accelerate the rapid expansion of this modality.
Don Kiepert, president and CEO of Lantheus Medical Imaging, said: “This co-promotion agreement is a strategic fit for Lantheus and demonstrates our continued commitment to advancing the field of diagnostic imaging through our distribution network, customer service and sales and medical affairs field organization.”